Skipka G - Search Results

1

The Peto odds ratio viewed as a new effect measure.

Brockhaus AC, Bender R, Skipka G. Brockhaus AC, et al. Among authors: skipka g. Stat Med. 2014 Dec 10;33(28):4861-74. doi: 10.1002/sim.6301. Epub 2014 Sep 22. Stat Med. 2014. PMID: 25244540

2

Reporting of loss to follow-up information in randomised controlled trials with time-to-event outcomes: a literature survey.

Vervölgyi E, Kromp M, Skipka G, Bender R, Kaiser T. Vervölgyi E, et al. Among authors: skipka g. BMC Med Res Methodol. 2011 Sep 21;11:130. doi: 10.1186/1471-2288-11-130. BMC Med Res Methodol. 2011. PMID: 21936924 Free PMC article. Review.

3

A note on the graphical presentation of prediction intervals in random-effects meta-analyses.

Guddat C, Grouven U, Bender R, Skipka G. Guddat C, et al. Among authors: skipka g. Syst Rev. 2012 Jul 28;1:34. doi: 10.1186/2046-4053-1-34. Syst Rev. 2012. PMID: 22839660 Free PMC article.

4

Methods for evidence synthesis in the case of very few studies.

Bender R, Friede T, Koch A, Kuss O, Schlattmann P, Schwarzer G, Skipka G. Bender R, et al. Among authors: skipka g. Res Synth Methods. 2018 Sep;9(3):382-392. doi: 10.1002/jrsm.1297. Epub 2018 Apr 6. Res Synth Methods. 2018. PMID: 29504289 Free PMC article.

5

Performing Meta-analyses with Very Few Studies.

Schulz A, Schürmann C, Skipka G, Bender R. Schulz A, et al. Among authors: skipka g. Methods Mol Biol. 2022;2345:91-102. doi: 10.1007/978-1-0716-1566-9_5. Methods Mol Biol. 2022. PMID: 34550585

6

Intervention effects in the case of heterogeneity between three subgroups. Assessment within the framework of systematic reviews.

Skipka G, Bender R. Skipka G, et al. Methods Inf Med. 2010;49(6):613-7. doi: 10.3414/ME09-02-0054. Epub 2010 Jul 20. Methods Inf Med. 2010. PMID: 20644897

7

No inconsistent trial assessments by NICE and IQWiG: different assessment goals may lead to different assessment results regarding subgroup analyses.

Bender R, Koch A, Skipka G, Kaiser T, Lange S. Bender R, et al. Among authors: skipka g. J Clin Epidemiol. 2010 Dec;63(12):1305-7. doi: 10.1016/j.jclinepi.2010.06.003. Epub 2010 Oct 6. J Clin Epidemiol. 2010. PMID: 20926256 No abstract available.

8

Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs.

Skipka G, Wieseler B, Kaiser T, Thomas S, Bender R, Windeler J, Lange S. Skipka G, et al. Biom J. 2016 Jan;58(1):43-58. doi: 10.1002/bimj.201300274. Epub 2015 Jul 2. Biom J. 2016. PMID: 26134089 Free PMC article.

9

On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies.

Unkel S, Amiri M, Benda N, Beyersmann J, Knoerzer D, Kupas K, Langer F, Leverkus F, Loos A, Ose C, Proctor T, Schmoor C, Schwenke C, Skipka G, Unnebrink K, Voss F, Friede T. Unkel S, et al. Among authors: skipka g. Pharm Stat. 2019 Mar;18(2):166-183. doi: 10.1002/pst.1915. Epub 2018 Nov 20. Pharm Stat. 2019. PMID: 30458579 Free PMC article.

10

Ginkgo biloba in Alzheimer's disease: a systematic review.

Janssen IM, Sturtz S, Skipka G, Zentner A, Velasco Garrido M, Busse R. Janssen IM, et al. Among authors: skipka g. Wien Med Wochenschr. 2010 Dec;160(21-22):539-46. doi: 10.1007/s10354-010-0844-8. Wien Med Wochenschr. 2010. PMID: 21170694 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters